Use of adjunctive glycaemic agents with vascular protective properties in individuals with type 1 diabetes: potential benefits and risks
Rajab AM, Pearson S, Ajjan RA
Diabetes Obes Metab. Pub. online 25 Mar 2025.
Leggi
Breaking news
The use of continuous glucose monitoring in people living with obesity, intermediate hyperglycemia or type 2 diabetes
Battelino T, Lalic N, Hussain S, et al.
Diabetes Res Clin Pract. 2025:112111.
Leggi
Reconsideration of lowering gestational weight gain guidelines in pregnant women diagnosed with gestational diabetes: evidence from a Belgian study
Benhalima K, Minschart C, Geerts I, et al.
BMC Med. 2025;23(1):165.
Leggi
Managing discordance between HbA1c and glucose management indicator
Lenters-Westra E, Fokkert M, Kilpatrick ES, et al.
Diabet Med. 2025:e70023.
Leggi
Causal associations between gut microbiota and type 2 diabetes mellitus subtypes: a mendelian randomization analysis
Ruan Z, Liu J, Zhao J
BMC Endocr Disord. 2025;25(1):79.
Leggi
AIFA: Riclassificazione del medicinale per uso umano “Awiqli” (insulina Icodec) classe di rimborsabilità: A (Determina n. 273/2025)
25/03/2025
Leggi
AIFA: Modifica dei prescrittori per i medicinali a base dei principi attivi evolocumab, alirocumab e inclisiran, autorizzati con regime di fornitura RRL. (Determina n. 252/2025)
21/03/2025
Leggi
Kidney outcomes with SGLT2 inhibitors in patients with diabetes and an insulin-deficient phenotype: a real world analysis
Tsur A, Cahn A, Hanoch L, Pollack R
Diabetes Obes Metab. Pub. online 14 Mar 2025.
Leggi